Send to

Choose Destination
Eur J Pharmacol. 2000 Jul 21;400(2-3):221-4.

The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing.

Author information

Neuroscience Research, Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Mail Drop 0510, Indianapolis, IN 46285, USA.


We have previously reported that the specific group II metabotropic glutamate receptor agonist LY379268 inhibited phencyclidine (PCP)-induced motor activations in rats, but had mixed effects on behaviors produced by amphetamine. Here, LY379268 (1 mg/kg subcutaneous (s.c.)) attenuated amphetamine-induced ambulations and rearing but did not alter amphetamine-evoked fine motor movements. Consistent with a mechanism involving mGlu(2/3) receptors, the inhibitory actions of LY379268 on ambulations and rearing were reversed by LY341495, a mGlu(2/3) receptor antagonist. These data further suggest antipsychotic actions of mGlu(2/3) receptor agonists with a low propensity for extra-pyramidal side effects.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center